The FDA has granted approval for Spravato, a ketamine-derived nasal spray developed by Johnson & Johnson, making it the first standalone treatment for adults suffering from treatment-resistant depression. This pioneering approval marks a significant advancement in mental health care, as Spravato is now recognized as the sole monotherapy for major depressive disorder, expanding treatment options for patients who have not responded to traditional therapies. The decision is seen as a game-changer in the field of mental health, bringing hope to those grappling with severe depression.